Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab + tremelimumab with or without chemotherapy for metastatic non-small cell lung cancer
ACTRN12617001468314Phase 2Completed
- Sponsor
- NHMRC Clinical Trials Centre
- Start
- Jan 2018
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of durvalumab and tremelimumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by NHMRC Clinical Trials Centre. Primary endpoint: Overall survival. Started Jan 2018; status: completed.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ACTRN12617001468314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001468314.